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Bent Bone Dysplasia-FGFR2 type, a Distinct Skeletal
Disorder, Has Deficient Canonical FGF Signaling
Amy E. Merrill,1,6,7,8 Anna Sarukhanov,1 Pavel Krejci,6,9,10 Brian Idoni,7 Natalia Camacho,1
Kristine D. Estrada,3 Karen M. Lyons,1,3 Hannah Deixler,1 Haynes Robinson,11 David Chitayat,12,13
Cynthia J. Curry,14 Ralph S. Lachman,6 William R. Wilcox,4,6 and Deborah Krakow1,2,5,6,*
Fibroblast growth factor receptor 2 (FGFR2) is a crucial regulator of bone formation during embryonic development. Both gain and loss-
of-function studies in mice have shown that FGFR2 maintains a critical balance between the proliferation and differentiation of osteo-
progenitor cells. We have identified de novo FGFR2mutations in a sporadically occurring perinatal lethal skeletal dysplasia characterized
by poor mineralization of the calvarium, craniosynostosis, dysmorphic facial features, prenatal teeth, hypoplastic pubis and clavicles,
osteopenia, and bent long bones. Histological analysis of the long bones revealed that the growth plate contained smaller hypertrophic
chondrocytes and a thickened hypercellular periosteum. Four unrelated affected individuals were found to be heterozygous for missense
mutations that introduce a polar amino acid into the hydrophobic transmembrane domain of FGFR2. Using diseased chondrocytes and
a cell-based assay, we determined that these mutations selectively reduced plasma-membrane levels of FGFR2 and markedly diminished
the receptor’s responsiveness to extracellular FGF. All together, these clinical and molecular findings are separate from previously char-
acterized FGFR2 disorders and represent a distinct skeletal dysplasia.Most fibroblast growth factor (FGF) ligands mediate their
biological effects extracellularly by forming a complex
with heparin sulfate proteoglycans and transmembrane
fibroblast growth factor receptors (FGFRs). Upon activa-
tion, FGFRs autophosphorylate intracellular tyrosine resi-
dues and recruit adaptor proteins next to the membrane
to launch ERK1/2, PLCg, and PI3K/AKT cascades that
subsequently regulate cell growth and differentiation.1,2
Heterozygosity for mutations in FGFR1, FGFR2, and
FGFR3 (MIM 136350, 176943, 134934, respectively)
produces a wide spectrum of genetic disorders, some with
skeletal defects and others with congenital anomalies.
Autosomal-dominant FGFR2 mutations that enhance
receptor signaling through ligand-independent dimeriza-
tion, constitutive receptor activation, or reduced ligand
specificity are responsible for craniosynostosis syndromes
that include Apert syndrome (ACS1 [MIM 101200])
Crouzon syndrome (CFD1 [MIM 123500]), Jackson-Weiss
syndrome (JWS [MIM 123150]), Pfeiffer syndrome (ACS5
[MIM 101600]), and Beare-Stevenson syndrome (BSTVS
[MIM 123790]).3–8 In contrast, the effect of diminished
FGFR2 function in human development is seen in
Lacrimoauriculodentodigital syndrome (LADD [MIM
149730]). This disorder, characterized by lacrimal-duct
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FGFR2 mutations that reduce tyrosine kinase activity.9,10
Although these disorders exemplify a role for FGFR2 in
the development of the craniofacial complex and distal
limbs, less is known about the importance of FGFR2
signaling in the remaining human appendicular skeleton.
Under an institutional review board (IRB)-approved
human-subjects protocol and upon receiving informed
consent, we performed a prenatal and postnatal evaluation
of a fetus at 23 weeks of gestation. Our examination re-
vealed an unusual constellation of dysmorphic features
including low-set ears, hypertelorism, midface hypoplasia,
micrognathia, prematurely erupted fetal teeth, and clitoro-
megaly (Figures 1A, 1D, and 1E and Tables 1 and 2). Radio-
graphic findings included bent long bones, osteopenia,
irregular periosteal surfaces especially in the phalanges,
deficient skull ossification, coronal craniosynostosis, and
hypoplastic clavicles and pubis (Figures 1H, 1J, and 1M).
Subsequently, we identified three additional unrelated
cases, R08-041, R96-252, and R05-427, with nearly
identical clinical and radiographic findings (Figures 1B,
1C, 1F, 1G, 1I, 1K, 1L, and 1N; delineated in Tables 1
and 2). In one case (R08-041), hepatosplenomegaly
with extramedullary hematopoiesis was noted at autopsy.
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Figure 1. Clinical and Radiographic Findings in BBD-FGFR2 Type
(A–E) Craniofacial abnormalities include hypertelorism, microganthia, microstomia, low-set posteriorly rotated ears, prenatal teeth,
and a flattened midface.
(F–N) Radiographic analysis revealed reduced mineralization of the calvarial vault (F and G), coronal craniosynostosis (arrow in G),
hypoplastic clavicles (arrows in H and I), bent long bones in the lower extremities and hypoplastic pubis (J–L, arrow in K), and boney
nodules on the phalanges and metacarpals (M and N).nonconsanguineous. In two cases (R07-401 and R08-041),
a histological analysis of the long bones was performed.
The distal femoral growth plate was dissected at the
time of necropsy, bisected longitudinally, and embedded
in plastic resin. Sections were stained with toluidine
blue (the control and R07-401) or hematoxylin and eosin
(R08-041). Microscopic examination showed that al-
though there was normal organization of columnar chon-
drocytes, hypertrophic chondrocytes were subjectively
smaller (Figures 2A–2C). The average cell size of diseased
hypertrophic chondrocytes (n ¼ 40) was measured
with the public domain ImageJ11 and found to be 0.483The Ame(R07-401) and 0.383 (R08-041) smaller than that found
in the control. Most notably, the surrounding periosteum
was thickened and hypercellular (Figures 2D–2F).
Candidate genes for mutation analysis were selected
on the basis of both their expression pattern within the
developing skeleton and mouse mutants with phenotypic
similarities to the affected fetuses. For the following
candidate genes, we amplified the coding exons from
genomic DNA by using PCR (for oligonucleotide se-
quences, see Table S1, available online), sequenced them
bidirectionally (MC Labs, San Francisco, CA), and com-
pared them with their reference sequence by usingrican Journal of Human Genetics 90, 550–557, March 9, 2012 551
Table 1. Phenotypic and Radiographic Findings in Bent Bone Dysplasia-FGFR2 Type
Abnormalities Findings
Phenotypic
Craniofacial open metopic suture, hypertelorism, megalophthalmos, midface hypoplasia, micrognathia, gingival hyperplasia,
prenatal teeth, low-set ears, overfolded superior helix, deficient auricle




Cranium diminished mineralization of the calvarium, craniosynostosis (coronal), midface hyoplasia, micrognathia
Thorax bell-shaped thorax, hypoplastic clavicles, diminished mineralization of the inferior margin of the scapula
Spine normal
Pelvis narrow acetabular roof, narrowed ischia, diminished mineralization of the pubis
Appendicular skeleton variable degrees of bending of the long bones, particularly of the femora, prominent periosteum
Metacarpals and phalanges brachydactyly, areas of periosteal reaction and deficient ossificationSequencher (Gene Codes, Ann Arbor, MI): PRRX1 (MIM
167420), PRRX2 (MIM 604675), TBX15 (MIM 604127),
ALX1 (MIM 601527), FGFR2, and FGFR3. Nucleotides
were numbered according to the mRNA sequence, starting
from A of the ATG initiation codon. Our analysis of the
17 exons that encode FGFR2 demonstrated that all the
affected individuals were heterozygous for missense muta-
tions within the coding region of exon 9 (RefSeq accession
number NM_000141.4; Ensembl accession number
ENST00000358487). Three independent cases (R07-401,
R08-041, and R96-252) shared the same de novo missense
mutation, c.1172T>G (Figures 3A–3C). This change pre-Table 2. Phenotypic Spectrum among the Affected Individuals
Abnormal Findings R08-041 R07-401 R96-252a R05-427
Hypertelorism þ þ N/A þ
Dysmorphic facies þ þ N/A þ
Megalophthalmous þ þ N/A þ
Prenatal teeth  þ N/A 
Gastrointestinal þ  N/A N/A
Clitoromegaly þ þ N/A þ
Hirsutism þ þ N/A þ
Hypomineralization
of the calvarium
þ þ þ þ
Craniosynostosis þ þ  þ
Hypoplastic clavicles þ þ þ þ
Narrow ischia/
hypoplastic pubis
þ þ þ þ
Bent long bones þ þ þ þ
Abnormal phalanges þ þ þ þ
The following abbreviation is used: N/A, not available.
aOnly radiographs were available.
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number NP_000132.3), which replaces a highly conserved
hydrophobic residue with a positively charged polar amino
acid in the transmembrane (TM) helix (UniProt Prot
P21802) (Figure 3E). The fourth affected individual,
R05-427, was heterozygous for the missense mutation
c.1141T>G (Figure 3D). This change predicted the substi-
tution p.Tyr381Asp, which replaces a highly conserved
hydrophobic residue with a negatively charged polar
amino acid in the TM helix (Figure 3E). Mutations were
not present in available parental DNA from two of the
cases (R07-401 and R08-041) (Figure 3A, B) nor were they
found among 210 ethnically matched control alleles.
The clinical and genetic findings of these four affected
individuals are distinct and constitute a distinct disorder
we designate as bent bone dysplasia (BBD)-FGFR2 type.
To examine the effect of c.1172T>G on the abundance
of FGFR2 transcripts, we performed quantitative PCR
(qPCR) on cDNA reverse transcribed from diseased tibia
growth-plate RNA (R07-401). Specifically, we isolated
RNA from the growth-plate cartilage by using Trizol
(Invitrogen), synthesized cDNA by reverse transcription
(Superscript, Invitrogen), and conducted qPCR by using
SYBR green and primer sets spanning introns of human
Actin (MIM 102630) and FGFR2 (for oligonucleotide
sequences, see Table S1). These experiments showed that
levels of FGFR2 transcripts from diseased growth-plate
RNA were slightly higher than from that of an age-
matched control (Figure 4A). We could not deduce the
statistical significance of this increase because we only
had access to RNA from one individual with BBD-FGFR2
type. Therefore, we concluded that FGFR2 c.1172T>G
does not lead to transcript degradation.
The TM helix of FGFR2 allows for receptor integration
into the lipid bilayer during translation at the rough endo-






A B C R08-041R07-401Control Figure 2. Histologic Analysis of the Distal
Femoral Growth Plate in BBD-FGFR2 Type
Longitudinal sections through the femoral
growth plate of a normal control matched for
growth stage (A) and two BBD-FGFR2-type indi-
viduals, R07-401 (B) and R08-041 (C), showed
that cellular organization was largely normal
with subjectively smaller hypertrophic chondro-
cytes.
(D–F) The long-bone periosteum (p) in BBD-
FGFR2-type individuals R07-401 and R08-041
was hypercellular and enlarged compared to
that of the control.a homologous region of FGFR1 decreases receptor levels at
themembrane while increasing levels found in the nucleus
and cytosol.12 To determine how BBD-FGFR2-type muta-
tions might alter secondary structure of the transmem-
brane domain, we analyzed the amino acid sequence for
FGFR2 by using the TMHMM (transmembrane prediction
based on hidden Markov models) transmembrane helices
server available online through CBS Bioinformatics
Tools.13 Upon induction of p.Met391Arg or p.Tyr381Asp
into FGFR2, TMHMM no longer predicted the location
of the known transmembrane helix (Figures 3F–3H). This
suggested that the mutations disrupt the secondary
structure of the FGFR2 TM helix and prevent membrane
integration. Although the hydrophobicity of the TM
domain facilitates initial membrane incorporation, sub-
sequent glycosylation of FGFR2 is critical for receptor
trafficking to the cell surface.14 To analyze the protein
levels for each FGFR2 isoform in BBD-FGFR2 type, we per-
formed immunoblots on the lysates from diseased primary
chondrocytes. We liberated primary chondrocytes from
the distal femurs of an affected individual (R07-401)
and a staged-matched control by using 0.03% bacterial
collagenase II. After a short-term culture in DMEM
(Dulbecco’s modified Eagle’s medium) with 10% FBS, cells
were lysed with RIPA (radio-immunoprecipitation assay).
Protein extracts were resolved on a 10% SDS-PAGE, trans-
ferred to a nitrocellulose membrane (BioRad), and probed
with the Bek antibody (FGFR2) (recognizes amino acids
771–821, Santa Cruz Biotechnology, 1/200), anti-FGFR2
extracellular (FGFR2ex) (recognizes amino acids 362–374,
Sigma-Aldrich, 1/2000), or b-actin antibody (Cell Signal-
ing Technology, 1/1000). After incubation with HRP-
conjugated secondary antibody, immunoreactivity was
detected with Phototope-HRP Western blot detection
system (Cell Signaling Technology). Both FGFR2 anti-
bodies were tested; one recognized the intracellular
tyrosine kinase domain (FGFR2) and the other, the extra-
cellular juxtamembrane domain (FGFR2ex), showed thatThe American Journal of Hlevels of the fully glycosylated receptor
were reduced in diseased cells compared to
control cells (Figure 4B, *bands). Biotin
labeling and purification of cell-surface
proteins from control and diseased chon-drocytes confirmed a similar reduction in FGFR2 at the
plasma membrane of diseased cells (Figure 4B) (Pierce
Cell Surface Protein Isolation Kit).
The subcellular localization of FGFR2 was determined
in BBD-FGFR2-type cells by immunofluorescence and
confocal microscopy. Diseased and control primary chon-
drocytes were seeded on chamber slides (Lab-Tek), fixed
in 4% paraformaldehyde for 5 min, blocked with 10%
goat serum (Zymed), and incubated overnight at 4C
with either anti-Bek (FGFR2) (1/200) or anti-FGFR2 extra-
cellular (FGFR2ex) (1/400) diluted in 1% goat serum in
PBST. Primary antibodies were detected with Alexa Fluor
568 conjugated goat anti-rabbit secondary antibody
diluted 1/400 in 1% goat serum in PBST. We used wheat
germ agglutinin (WGA) 488 conjugate (Invitrogen) to
label the plasma membrane. The FGFR2 antibody, recog-
nizing the intracellular domain, detected receptor, marked
by WGA, at the plasma membrane, and in the nuclei of
control chondrocytes (Figure 4C). In BBD-FGFR2-type
chondrocytes, this antibody identified very little FGFR2
at the membrane and showed that the receptor was
primarily distributed in the nucleus (Figure 4D). Using
the FGFR2ex antibody that recognizes the extracellular
domain, we confirmed receptor localization in the plasma
membrane and the nuclei of control cells (Figure 4E). In
diseased cells, this antibody verified that FGFR2 was
reduced at the plasma membrane, retained in the nucleus,
and occasionally sequestered to juxtanuclear inclusions
(Figure 4F, arrow). These inclusions, along with reduced
FGFR2 glycosylation, suggest altered receptor trafficking
from the endoplasmic reticulum.
We next determined the subcellular localization of
mutant FGFR2Met391Arg by using a cell-based assay in
BaF3 cells, which lack endogenous expression of all FGF
receptors and ligands.15 Plasmids containing the cDNA
for either FGFR2WT or FGFR2Met391Arg were introduced
into BaF3 cells via the Nucleofector I device (program
X-01) with Nucleofector Kit V (Amaxa, Lonza). Afteruman Genetics 90, 550–557, March 9, 2012 553
Figure 3. FGFR2 Mutational Analysis in BBD-FGFR2-Type Families
Sequencing chomatograms demonstrated de novo heterozygous mutations in exon 9 of FGFR2 in affected individuals from the
four unrelated families studied. Affected individuals R07-401 (A), R08-041 (B), and R96-252 (C) shared the same de novo heterozygous
mutation, c.1172T>G (p.Met391Arg).
(D) R05-427 was heterozygous for c.1141T>G (p.Tyr381Asp).
(E) All mutations (bolded) were localized to a highly conserved region within the transmembrane domain.
(F–H) TMHMM plots predicted the probability (y axis) that the amino acid sequences (x axis) of FGFR2, FGFR2Met391Arg, and
FGFR2Tyr381Asp are located outside the cell (pink bar), inside the cell (blue bar), or within the membrane (red bar).24 hr of growth in RPMI 1640 medium (Invitrogen) sup-
plemented with 10% newborn calf serum and murine IL-
3-conditioned medium, cells were seeded on chamber
slides (Lab-Tek), fixed in 4% PFA for 10 min, washed with
PBS with 0.1% TritonX 100 for 30 s, and then washed
three times with PBS for 15 min per wash. We then
performed immunofluorescence analyses with the Bek
(FGFR2) antibody and the membrane maker WGA. BaF3
cells expressing FGFR2WT showed receptor localization to
the plasma membrane (Figure 4G), whereas the cells
expressing FGFR2Met391Arg showed receptor restriction to
the nucleus (Figure 4H).
To test if mutant FGFR2Met391Arg had altered responsive-
ness to extracellular FGF signaling, we serum-starved BaF3
cells expressing either FGFR2WT or FGFR2Met391Arg and
then stimulated cells with two FGFs known to regulate554 The American Journal of Human Genetics 90, 550–557, March 9bone development.1 After stimulation with FGF2 (MIM
134920) or FGF18 (MIM 603726) (100 ng/ml of ligand
with 10 mg/ml heparin; R&D Systems, Peprotech) for
30 min, we lysed cells and analyzed levels of phosphory-
lated ERK1/2 (p-ERK1/2), a canonical target of FGF sig-
naling in bone, by immunoblot analyses. Membranes
probed with anti-p-ERK1/2 (Cell Signaling Technology,
1/1000) and anti-a-tubulin (Cell Signaling Technology,
1/1000) showed that, unlike FGFR2WT-expressing cells,
FGFR2Met391Arg-expressing cells are unable to activate
phosphorylation of ERK1/2 (Figure 4I). Lack of FGF respon-
siveness by FGFR2Met391Arg suggests that BBD-FGFR2 type,
in part, results from reduced FGFR2 signaling at the plasma
membrane.
The clinical and radiographic findings in this FGFR2






Figure 4. Mutant FGFR2Met391Arg Showed
Deficient Plasma-Membrane Localization and
Reduced Responsiveness to Extracellular FGF
(A) Quantitative PCR of tibial growth-plate cDNA
in the control and R07-401 showed that R07-401
had slightly elevated levels of FGFR2 expression.
(B) Immunoblot analysis—with FGFR2 anti-
bodies that recognize either the intracellular
domain (anti-FGFR2) or extracellular domain
(anti-FGFR2ex) of total lysates from primary
chondrocytes showed that there were fewer
highly glycosylated forms of FGFR2 in R07-401
chondrocytes than in the control (*bands). Biotin
labeling and purification of cell-surface proteins
identified less surface FGFR2 in R07-401 cells
than in the control.
(C) Immunofluorescent detection with an anti-
body recognizing the intracellular domain of
FGFR2 (red) and the membrane marker WGA
(green) in primary chondrocytes localized
FGFR2 to the membrane and nuclei of control
chondrocytes.
(D) Although membrane localization was unde-
tectable in R07-401 cells, nuclear receptor levels
were retained.
(E) The FGFR2ex antibody detected receptor in
the plasmamembrane and nuclei of control cells.
(F) In R07-401 cells, the FGFR2ex antibody de-
tected receptor in the nuclei and juxtanuclear
intracellular inclusions (arrow).
(G and H) BaF3 cells overexpressing either wild-
type or mutant FGFR2 were immuolabeled for
FGFR2 (red) and WGA (green) and showed that
FGFR2WT localized to the membrane whereas
FGFR2Met391Arg was restricted to the nucleus
(blue).
(I) Immunoblot analysis of lysates from BaF3
cells overexpressing FGFR2WT or FGFR2Met391Arg
showed that FGFR2Met391Arg-expressing cells
were unable to induce phosphorylation of
ERK1/2 upon 30 min of stimulation with either
FGF2 or FGF18.FGFR2 syndromes and represent a distinct skeletal
dysplasia. Previously recognized FGFR2 disorders manifest
postnatal growth disturbances associated with mild
short stature, craniosynostosis, radioulnar synostosis, and
hand and foot abnormalities; however, the appendicularThe American Journal of Hskeletal defects in BBD-FGFR2 type are
particularly profound and distinct. Among
the nonskeletal abnormalities in BBD-
FGFR2 type, clitoromegallywas seen in three
unrelated individuals with female karyo-
types. Although hypogonadism and genito-
urinary abnormalities result from loss of
FGFR1 function in Kallmann syndrome
(KAL2 [MIM 136350]),16 these particular
findings have not been previously described
in the FGFR2 disorders. FGF signaling plays
a key role in the development of the genital
tubercle. For example, FGF10 (MIM
602115), a ligand for FGFR2, is critical for
the outgrowth of the genital tubercle.Fgf10-deficient mice have morphologic defects in the
urethral epithelium and prepuce.17 Therefore, the genital
abnormalities found in three independent BBD-FGFR2-
type cases might be mechanistically linked to disturbances
in FGF signaling during genitalia development.uman Genetics 90, 550–557, March 9, 2012 555
The skeletal abnormalities seen in BBD-FGFR2 type
support a necessary role for FGFR2 signaling during
endochondral and intramembranous bone formation.
The fact that these abnormalities, at least partially, result
from deficient FGFR2 signaling in the plasma membrane
is further supported by loss-of-function studies in mice.
Although complete Fgfr2 deficiency in mice causes embry-
onic lethality,18,19 conditional inactivation of the receptor
in skeletogenic mesenchyme (Dermo1-Cre) causes a dome-
shaped skull and longitudinal shortening of axial and
appendicular skeletal elements.20 The two major FGFR2
transcriptional variants, generated by alternative spicing
of the ligand-binding domain, have distinct roles during
bone formation. The TM domain is conserved between
these variants, and the mutations identified in BBD-
FGFR2 type are therefore predicted to disrupt the function
of both FGFR2 isoforms. This is supported by the pheno-
typic similarities between BBD-FGFR2 type and mice
with selective inactivation of each FGFR2 splice variant.
Selective ablation of the epithelial-specific splice variant
Fgfr2-IIIb results in severe reduction of the scapula, malfor-
mation of the clavicles, and absence of the pubis.21–23 Mice
selectively deficient in the mesenchyme-specific splice
variant Fgfr2-IIIc have delayed mineralization of the
calvarium, craniosynostosis, and shortened long bones.24
Therefore, this skeletal phenotype of BBD-FGFR2 type
most likely results from altered FGFR2 signaling in both
epithelial- and mesenchymal-derived tissues during bone
formation.
Both gain and loss-of-function studies have shown that
FGFR2 maintains a balance between the proliferation and
differentiation of osteoprogenitor cells—loss leads to
decreased proliferation and differentiation,20,21,24 and
gain leads to enhanced proliferation and differentia-
tion.25,26 Interestingly, the BBD-FGFR2-type skeletal
phenotype shows some evidence of receptor gain of func-
tion: The periosteum, a principal source of osteoprogenitor
cells, is hypercellular and enlarged. Furthermore, few
phenotypic similarities between BBD-FGFR2 type and
LADD syndrome support the idea that the abnormalities
in BBD-FGFR2 type do not uniformly result from a strict
loss of FGFR2 function. An explanation for this conun-
drum might lie within the less-understood intracellular
signaling role for FGFRs. Although the FGFR2 mutations
identified in BBD-FGFR2 type lead to deficiency in
plasma-membrane targeting, our data show that nuclear
FGFR2 in cells remains unaltered. It thus remains a possi-
bility that the mutant FGFR2 retains intracellular activity.
For example, it has been previously revealed that unglyco-
sylated FGFR2, despite deficient targeting to the plasma
membrane, activates the PLCg pathway through intracel-
lular mechanisms.14 Dissimilarities between BBD-FGFR2
type and the established FGFR2 disorders suggest that
these distinct mutations will provide new insight into
FGF signaling not previously understood by a strict gain
or loss of FGFR2 function. Further studies with the use of
mouse models and cell-based assays will help us resolve556 The American Journal of Human Genetics 90, 550–557, March 9how distinct cellular-signaling routes for FGFR2 influence
the phenotypic complexities of this human skeletal
disorder.Supplemental Data
Supplemental Data include one table and can be found with this
article online at http://www.cell.com/AJHG.Acknowledgments
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